Tags

Type your tag names separated by a space and hit enter

Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer.
Helicobacter 1998; 3(3):212-21H

Abstract

BACKGROUND

The combination of ranitidine bismuth citrate (RBC) and clarithromycin (CLR) was compared with each treatment alone for the eradication of H. pylori and healing of duodenal ulcers in patients infected with H. pylori.

METHODS

This two-phase, randomized, double-blind, placebo-controlled, multicenter study evaluated 203 patients with an active duodenal ulcer treated with either (1) RBC 400 mg BID for 4 weeks plus CLR 500 mg TID for the first 2 weeks; (2) RBC 400 mg BID for 4 weeks plus placebo TID for the first 2 weeks; (3) placebo BID for 4 weeks plus CLR 500 mg TID for the first 2 weeks; or (4) placebo BID for 4 weeks plus placebo TID for the first 2 weeks. Patients with healed ulcers after treatment entered a 24-week observation phase for the assessment of H. pylori and ulcer relapse.

RESULTS

Four-week ulcer healing rates were higher with RBC + CLR (71%) and RBC alone (66%) compared with placebo (15%; p < 0.05) and CLR alone (49%). H. pylori eradication rates were significantly higher with RBC + CLR (86%) compared with RBC alone (0%, p < .001) or CLR alone (24%, p < .001). Ulcer recurrence rates after 6 months were lower in patients eradicated of H. pylori infection (17%) compared with patients who remained infected (43%). All treatments were well tolerated.

CONCLUSIONS

Ranitidine bismuth citrate plus clarithromycin is a simple, convenient, and well-tolerated dual therapy regimen that is effective in eradicating H. pylori and healing duodenal ulcers in patients infected with H. pylori. The eradication of H. pylori in patients with healed ulcers significantly reduces the rate of ulcer relapse.

Authors+Show Affiliations

Houston Institute for Clinical Research, TX 77074, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9731994

Citation

Lanza, F L., et al. "Ranitidine Bismuth Citrate Plus Clarithromycin: a Dual Therapy Regimen for Patients With Duodenal Ulcer." Helicobacter, vol. 3, no. 3, 1998, pp. 212-21.
Lanza FL, Sontag SJ, Ciociola AA, et al. Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer. Helicobacter. 1998;3(3):212-21.
Lanza, F. L., Sontag, S. J., Ciociola, A. A., Sykes, D. L., Heath, A., & McSorley, D. J. (1998). Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer. Helicobacter, 3(3), pp. 212-21.
Lanza FL, et al. Ranitidine Bismuth Citrate Plus Clarithromycin: a Dual Therapy Regimen for Patients With Duodenal Ulcer. Helicobacter. 1998;3(3):212-21. PubMed PMID: 9731994.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer. AU - Lanza,F L, AU - Sontag,S J, AU - Ciociola,A A, AU - Sykes,D L, AU - Heath,A, AU - McSorley,D J, PY - 1998/9/10/pubmed PY - 1998/9/10/medline PY - 1998/9/10/entrez SP - 212 EP - 21 JF - Helicobacter JO - Helicobacter VL - 3 IS - 3 N2 - BACKGROUND: The combination of ranitidine bismuth citrate (RBC) and clarithromycin (CLR) was compared with each treatment alone for the eradication of H. pylori and healing of duodenal ulcers in patients infected with H. pylori. METHODS: This two-phase, randomized, double-blind, placebo-controlled, multicenter study evaluated 203 patients with an active duodenal ulcer treated with either (1) RBC 400 mg BID for 4 weeks plus CLR 500 mg TID for the first 2 weeks; (2) RBC 400 mg BID for 4 weeks plus placebo TID for the first 2 weeks; (3) placebo BID for 4 weeks plus CLR 500 mg TID for the first 2 weeks; or (4) placebo BID for 4 weeks plus placebo TID for the first 2 weeks. Patients with healed ulcers after treatment entered a 24-week observation phase for the assessment of H. pylori and ulcer relapse. RESULTS: Four-week ulcer healing rates were higher with RBC + CLR (71%) and RBC alone (66%) compared with placebo (15%; p < 0.05) and CLR alone (49%). H. pylori eradication rates were significantly higher with RBC + CLR (86%) compared with RBC alone (0%, p < .001) or CLR alone (24%, p < .001). Ulcer recurrence rates after 6 months were lower in patients eradicated of H. pylori infection (17%) compared with patients who remained infected (43%). All treatments were well tolerated. CONCLUSIONS: Ranitidine bismuth citrate plus clarithromycin is a simple, convenient, and well-tolerated dual therapy regimen that is effective in eradicating H. pylori and healing duodenal ulcers in patients infected with H. pylori. The eradication of H. pylori in patients with healed ulcers significantly reduces the rate of ulcer relapse. SN - 1083-4389 UR - https://www.unboundmedicine.com/medline/citation/9731994/Ranitidine_bismuth_citrate_plus_clarithromycin:_a_dual_therapy_regimen_for_patients_with_duodenal_ulcer_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=1083-4389&amp;date=1998&amp;volume=3&amp;issue=3&amp;spage=212 DB - PRIME DP - Unbound Medicine ER -